Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Cost-Effectiveness Analysis | Global Governance | Mental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
ReportPublication 2017DCP3: Injury Prevention and Environmental Health
This report from the World Bank is the seventh volume of the Disease Control Priorities, …
This report from the World Bank is the seventh volume of the Disease Control Priorities, Third Edition (DCP3) series and focuses on injury prevention and environmental health. The burden of death and disability resulting from interpersonal violence, road traffic injuries, unintentional injuries, occupational health risks, and climate and pollution falls disproportionately on low- and middle- income countries. This report examines risk factors and offers an economic analysis of platforms to deliver cost-effective interventions to prevent…
Cost-Effectiveness Analysis | Global Governance | Environmental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Injuries/Accidents | Policy/Regulation | Climate/Environment | Culture/Society | Economics/Finance | Health/Medicine | Global -
ReportPublication 2016DCP3: Mental, Neurological, and Substance Use Disorders
This report from the World Bank is the fourth volume of the Disease Control Priorities, …
This report from the World Bank is the fourth volume of the Disease Control Priorities, Third Edition (DCP3) series. It discusses the prevalence of mental, neurological, and substance use disorders, as well as the associated disability and premature mortality that can accompany them. Despite the high social and economic burden of these diseases on individuals, families, and communities, these disorders have been systematically neglected, especially in low- and middle-income countries, and there has been limited…
Cost-Effectiveness Analysis | Global Governance | Mental Health | Costing Methods | Health Outcomes | Evidence Synthesis | Health Systems | Economics/Finance | Health/Medicine | Global -
ReportPublication 2015DCP3: Essential Surgery
This report from the World Bank is the first volume of the Disease Control Priorities, …
This report from the World Bank is the first volume of the Disease Control Priorities, Third Edition (DCP3) series. Essential Surgery presents data on the surgical burden of disease, disability, congenital abnormalities, and trauma, as well as the health impact and economic analysis of procedures. This report identifies 44 procedures that address substantial needs, are cost effective, and are feasible to implement in low- and middle-income countries. If made universally available, these 44 procedures could…
Cost-Effectiveness Analysis | Global Governance | Clinical Care | Costing Methods | Health Outcomes | Evidence Synthesis | Injuries/Accidents | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Global -
ArticlePublication 2016An Extended CEA of Schizophrenia Treatment in India under Universal Public Finance
This paper evaluates the potential health and financial risk protection effects of a policy of …
This paper evaluates the potential health and financial risk protection effects of a policy of universal public finance (UPF) to treating schizophrenia in India. The study uses the extended cost effectiveness analysis framework across income quintiles. The results show financial protection benefits concentrated in the richest income quintiles, while health gains were concentrated among the poorest. The value of insurance is highest for the poorest income and decreases as the household income increases. In settings…
Cost-Effectiveness Analysis | Clinical Care | Mental Health | Priority Setting/Ethics | Costing Methods | Health Systems | Culture/Society | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2011Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe …
In this article the authors use epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, they assessed HPV vaccination of girls before age 12 followed by screening with HPV DNA testing once, twice, or three times per lifetime (at ages 35, 40, 45). For women over age 30, they assessed only screening (with HPV DNA testing up to three times per lifetime or VIA…
Cost-Effectiveness Analysis | Calibration/Validation | Clinical Care | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | Science/Technology | Sub-Saharan Africa -
ArticlePublication 2009Cost Effectiveness Analysis of Including Boys in a HPV Vaccination Program in the U.S.
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a …
This article reports on a societal-perspective cost effectiveness analysis of including preadolescent boys in a routine human papillomavirus (HPV) vaccination program for preadolescent girls. The analysis included girls and boys aged 12 years; interventions included HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer. The authors found that with 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12-year-old girls…
Cost-Effectiveness Analysis | Calibration/Validation | Clinical Care | Dynamic Transmission | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Economics/Finance | Health/Medicine | North America -
ArticlePublication 2008Health and Economic Implications of HPV Vaccination in the U.S.
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical …
This article reports on a study using models of HPV-16 and HPV-18 transmission and cervical carcinogenesis to compare the health and economic outcomes of vaccinating preadolescent girls in the US (at 12 years of age), and vaccinating older girls and women in catch-up programs (to 18, 21, or 26 years of age). The study also examined the health benefits of averting other HPV-16-related and HPV-18-related cancers, the prevention of HPV-6-related and HPV-11-related genital warts and…
Cost-Effectiveness Analysis | Calibration/Validation | Clinical Care | Dynamic Transmission | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | North America -
ArticlePublication 2008Health and Economic Impact of HPV 16 and 18 Vaccination and Cervical Cancer Screening in India
As cervical cancer is a leading cause of cancer death among women in low-income countries, …
As cervical cancer is a leading cause of cancer death among women in low-income countries, with approximately 25% of cases worldwide occurring in India, these authors estimated the potential health and economic impact of different cervical cancer prevention strategies in India. After empirically calibrating a cervical cancer model to country-specific epidemiologic data, they projected cancer incidence, life expectancy, and lifetime costs (I$2005), and calculated incremental cost-effectiveness ratios (I$/YLS) for the following strategies: pre-adolescent vaccination of…
Cost-Effectiveness Analysis | Calibration/Validation | Clinical Care | Microsimulation | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Asia & Pacific